Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound
Thierry Bordet Trophos, Parc Scientifique de Luminy, Case 931, 13288 Marseille cedex 9, France
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(2), 345-368; https://doi.org/10.3390/ph3020345
Received: 23 December 2009 / Revised: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010
(This article belongs to the Special Issue Mitochondrial Drugs for Neurodegenerative Diseases)
Olesoxime (TRO19622) is a novel mitochondrial-targeted neuroprotective compound undergoing a pivotal clinical efficacy study in Amyotrophic Lateral Sclerosis (ALS) and also in development for Spinal Muscular Atrophy (SMA). It belongs to a new family of cholesterol-oximes identified for its survival-promoting activity on purified motor neurons deprived of neurotrophic factors. Olesoxime targets proteins of the outer mitochondrial membrane, concentrates at the mitochondria and prevents permeability transition pore opening mediated by, among other things, oxidative stress. Olesoxime has been shown to exert a potent neuroprotective effect in various in vitro and in vivo models. In particular olesoxime provided significant protection in experimental animal models of motor neuron disorders and more particularly ALS. Olesoxime is orally active, crosses the blood brain barrier, and is well tolerated. Collectively, its pharmacological properties designate olesoxime as a promising drug candidate for motor neuron diseases.
View Full-Text
Keywords:
TRO19622; olesoxime; neuroprotection; mitochondrial permeability transition pore; motor neuron disease; amyotrophic lateral sclerosis; spinal muscular atrophies
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License
MDPI and ACS Style
Bordet, T.; Berna, P.; Abitbol, J.-L.; Pruss, R.M. Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound. Pharmaceuticals 2010, 3, 345-368.
Show more citation formats
